This page contains other reports prepared by the Drug Price Transparency Program for the Oregon Legislature. The program also produces an annual report as required by ORS 646A.689 (14), which can be viewed on the
annual reports webpage.
Senate Bill 711 (2021) required the Department of Consumer and Business Services to conduct a study of disparities in the cost of hormone replacement drugs between those for men and those for women and provide an executive summary per ORS 192.245. Below are the executive summary and report provided to the Oregon Legislature on September 15, 2022.
Executive summary
Report